Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109-0720, USA.
Neuropsychopharmacology. 2013 Mar;38(4):639-46. doi: 10.1038/npp.2012.227. Epub 2012 Nov 16.
Personality traits have been shown to interact with environmental cues to modulate biological responses including treatment responses, and potentially having a role in the formation of placebo effects. Here, we assessed psychological traits in 50 healthy controls as to their capacity to predict placebo analgesic effects, placebo-induced activation of μ-opioid neurotransmission and changes in cortisol plasma levels during a sustained experimental pain challenge (hypertonic saline infused in the masseter muscle) with and without placebo administration. Statistical analyses showed that an aggregate of scores from Ego-Resiliency, NEO Altruism, NEO Straightforwardness (positive predictors) and NEO Angry Hostility (negative predictor) scales accounted for 25% of the variance in placebo analgesic responses. Molecular imaging showed that subjects scoring above the median in a composite of those trait measures also presented greater placebo-induced activation of μ-opioid neurotransmission in the subgenual and dorsal anterior cingulate cortex (ACC), orbitofrontal cortex, insula, nucleus accumbens, amygdala and periaqueductal gray (PAG). Endogenous opioid release in the dorsal ACC and PAG was positively correlated with placebo-induced reductions in pain ratings. Significant reductions in cortisol levels were observed during placebo administration and were positively correlated with decreases in pain ratings, μ-opioid system activation in the dorsal ACC and PAG, and as a trend, negatively with NEO Angry Hostility scores. Our results show that personality traits explain a substantial proportion of the variance in placebo analgesic responses and are further associated with activations in endogenous opioid neurotransmission, and as a trend cortisol plasma levels. This initial data, if replicated in larger sample, suggest that simple trait measures easily deployable in the field could be utilized to reduce variability in clinical trials, but may also point to measures of individual resiliency in the face of aversive stimuli such as persistent pain and potentially other stressors.
人格特质已被证明与环境线索相互作用,调节包括治疗反应在内的生物学反应,并可能在安慰剂效应的形成中发挥作用。在这里,我们评估了 50 名健康对照者的心理特征,以了解它们预测安慰剂镇痛效果、安慰剂诱导的μ-阿片类神经递质传递激活和皮质醇血浆水平变化的能力,这些变化是在持续的实验性疼痛挑战(在咀嚼肌中注入高渗盐水)期间,有无安慰剂给药。统计分析显示,Ego-Resiliency、NEO Altruism、NEO Straightforwardness(正预测因子)和 NEO Angry Hostility(负预测因子)量表的综合得分解释了安慰剂镇痛反应的 25%的方差。分子影像学显示,在这些特质测量的综合测量中得分高于中位数的受试者,在 subgenual 和背侧前扣带皮层(ACC)、眶额皮层、岛叶、伏隔核、杏仁核和中脑导水管周围灰质(PAG)中也表现出更大的安慰剂诱导的μ-阿片类神经递质传递激活。背侧 ACC 和 PAG 中的内源性阿片释放与安慰剂诱导的疼痛评分降低呈正相关。在安慰剂给药期间观察到皮质醇水平显著降低,与疼痛评分降低、背侧 ACC 和 PAG 中的μ-阿片类系统激活呈正相关,与 NEO Angry Hostility 评分呈负相关趋势。我们的结果表明,人格特质解释了安慰剂镇痛反应的很大一部分变异,并且与内源性阿片类神经递质传递的激活进一步相关,并且皮质醇血浆水平呈趋势相关。如果在更大的样本中得到复制,这些初步数据表明,在临床试验中可以利用易于部署的简单特质测量来减少变异性,但也可能指向面对持久疼痛和潜在其他应激源等不愉快刺激的个体弹性的测量。